Glycoengineering of EphA4 Fc leads to a unique, long-acting and broad spectrum, Eph receptor therapeutic antagonist

por Cassandra L. Pegg, Leanne T. Cooper, Jing Zhao, Michael Gerometta, Fiona M. Smith, Michael Yeh, Perry F. Bartlett, Jeffrey J. Gorman, Andrew W. Boyd
Publicado 2017

Digenic inheritance of mutations in EPHA2 and SLC26A4 in Pendred syndrome

por Mengnan Li, Shin-ya Nishio, Chie Naruse, Meghan Riddell, Sabrina Sapski, Tatsuya Katsuno, Takao Hikita, Fatemeh Mizapourshafiyi, Fiona M. Smith, Leanne T. Cooper, Min Goo Lee, Masahide Asano, Thomas Boettger, Marcus Krueger, Astrid Wietelmann, Johannes Graumann, Bryan W. Day, Andrew W. Boyd, Stefan Offermanns, Shin-ichiro Kitajiri, Shin-ichi Usami, Masanori Nakayama
Publicado 2020